New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
07:35 EDTALQAAlliqua says plans to launch BHAMA product late in Q2
Says plans to launch the Biovance Human Amniotic Membrane Allograft product late in Q2, and file for regulatory approval on the Extracellular Matrix product in 2H. Says intends to expand selling organization by adding around 20 new direct sales representatives to enhance the independent team we assembled in 2013. Says will seek to expand current product portfolio and suite of technological solutions through a mix of organic development opportunities and a targeted M&A focus.
News For ALQA From The Last 14 Days
Check below for free stories on ALQA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
07:41 EDTALQAAlliqua to launch Biovance human amniotic membrane allograft product
Alliqua (ALQA) will launch its Biovance human amniotic membrane allograft product. Biovance was originally developed by, and is currently being manufactured through a supply agreement with, Celgene Cellular Therapeutics, a subsidiary of Celgene (CELG), to assist wound care specialists, physicians and nurses, as well as vascular, plastic and general surgeons, in the treatment of a wide variety of complex, acute, chronic, recalcitrant, full and partial thickness wound types. With the right to develop and market Biovance, Alliqua has entered into one of the fastest-growing areas of wound care, which involves regenerative medicine. Alliqua will commence sales of Biovance immediately following the Symposium via its team of direct sales representatives.
April 15, 2014
09:00 EDTALQAAlliqua falls 6.6%
Alliqua is down 6.6%, or 45c, to $6.34

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use